{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=stem+cell&page=2",
    "query": {
      "intervention": "stem cell",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=stem+cell&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T19:53:23.296Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00204958",
      "title": "Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bone Marrow Transplantation",
        "Hematopoietic Stem Cell Transplantion"
      ],
      "interventions": [
        {
          "name": "nutritional supplement",
          "type": "DRUG"
        },
        {
          "name": "glutamine popsicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "4 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2004-02",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2015-10-01",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00204958"
    },
    {
      "nct_id": "NCT04798716",
      "title": "The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Novel Coronavirus Pneumonia",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)",
          "type": "DRUG"
        },
        {
          "name": "MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)",
          "type": "DRUG"
        },
        {
          "name": "MSC-exosomes delivered intravenously every other day (8:8:8)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEM HealthCare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2023-09",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2022-03-11",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 1,
      "location_summary": "Panorama City, California",
      "locations": [
        {
          "city": "Panorama City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04798716"
    },
    {
      "nct_id": "NCT03981549",
      "title": "Treatment of Central Retinal Vein Occlusion Using Stem Cells Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Autologous Bone Marrow CD34+ Stem Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sham Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The Emmes Company, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2019-10-22",
      "completion_date": "2023-11-09",
      "has_results": true,
      "last_update_posted_date": "2024-12-02",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03981549"
    },
    {
      "nct_id": "NCT00160355",
      "title": "Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wiskott-Aldrich Syndrome"
      ],
      "interventions": [
        {
          "name": "Hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Miltenyi CliniMACS selection system",
          "type": "DEVICE"
        },
        {
          "name": "Fludarabine, Melphalan, Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "Up to 18 Years · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2005-05",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00160355"
    },
    {
      "nct_id": "NCT05350163",
      "title": "T-cell Receptor α/β Depleted Donor Lymphocyte Infusion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoid Leukemia, Acute",
        "Myeloid Malignancy",
        "Plasma Cell Tumor"
      ],
      "interventions": [
        {
          "name": "T-cell Receptor α/β Depleted Donor Lymphocyte Infusions",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Guenther Koehne",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 11,
      "start_date": "2022-04-05",
      "completion_date": "2023-09-18",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05350163"
    },
    {
      "nct_id": "NCT01998633",
      "title": "Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophagocytic Lymphohistiocytosis",
        "Chronic Active Epstein-Barr Virus Infection",
        "Chronic Granulomatous Disease",
        "HIGM-1",
        "Leukocyte Adhesion Deficiency",
        "IPEX"
      ],
      "interventions": [
        {
          "name": "Hematopoietic Stem Cell Transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "4 Months to 45 Years"
      },
      "enrollment_count": 47,
      "start_date": "2013-12",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01998633"
    },
    {
      "nct_id": "NCT00064363",
      "title": "Talampanel in Treating Patients With Recurrent High-Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "talampanel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-06",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064363"
    },
    {
      "nct_id": "NCT00684021",
      "title": "Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Left Ventricular Dysfunction"
      ],
      "interventions": [
        {
          "name": "Adult stem cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2008-07",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2015-06-30",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00684021"
    },
    {
      "nct_id": "NCT01660633",
      "title": "Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)",
          "type": "DRUG"
        },
        {
          "name": "Autologous Transplantation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Acrotech Biopharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 61,
      "start_date": "2012-12",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01660633"
    },
    {
      "nct_id": "NCT05463133",
      "title": "Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Granulomatous Disease"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Pheripheral blood stem cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Emapalumab-Izsg",
          "type": "DRUG"
        },
        {
          "name": "Tociluzumab",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "4 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-07-08",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-09-07T19:53:23.296Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05463133"
    }
  ]
}